Education
- Postdoctoral Training, molecular cardiovascular biology,Cincinnati Children's Hospital Medical Center with Dr. Jeff Molkentin in Cincinnati, Ohio, 1999-2003
- PhD -Pharmacology and Toxicology, University of North Dakota, 1999
- M.S. in Forensic Medicine, Xian Medical University, China, 1989
- MD - Xian Medical University in China, 1986
Experience
- Junior Scientist, Cardiovascular Research Center, South Dakota Health Research Foundation, September 2003 to present
- Assistant Professor, Basic Biomedical Services, The University of South Dakota School of Medicine and Health Sciences, September 2003 to present
- Postdoctoral Researcher, Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center. October 1999 to September 2003
- Graduate Research Assistant, Department of Pharmacology and Toxicology, University of North Dakota School of Medicine. Advisor: Dr. Paul N. Epstein. July 1994 to September 1999
- Researcher and Lecturer, Faculty of Forensic Medicine, Xian Medical University, China July 1989 to June 1994
- Research and Teaching Assistant, Faculty of Forensic Medicine, Xian Medical University, China. September 1986 to July 1989
Distinctions
- Travel Award: 1996, Society of Toxicology Annual Meeting
- Outstanding Ph.D. Student Award: 1997-1998, University of North Dakota School of Medicine
- Predoctoral Fellowship: 1997-1999, National Science Foundation and ND EPSCoR
- Postdoctoral Fellowship: 2001-2003, American Heart Association Ohio Valley Affiliate
- Trainee Abstract Award: 2001 AHA Scientific Sessions
- Number of publications: 13
Professional Societies
- Society of Toxicology
- American Heart Association
Research Focus
- Current projects in the laboratory will provide insight into the precise pathways by which external physical and hormonal signals are communicated to heart muscle cells provoking intracellular responses, under varying conditions and at different stages of heart disease. These studies are expected to enhance our understanding of the cell signaling network in the heart, and help develop mechanism-based therapeutic strategies for heart disease.
Publications
- Liang Q, and Molkentin JD. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol. 2003 Dec; 35(12):1385-94
Liang Q, Bueno OF, Wilkins BJ, Kuan CY, Xia Y, Molkentin JD. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 2003 Oct 1;22(19):5079-89.
Suzuki YJ, Day RM, Tan CC, Sandven TH, Liang Q, Molkentin JD, and Fanburg BL. Activation of GATA4 by serotonin in pulmonary artery smooth muscle cells. J Biol Chem. 2003 May 9;278(19):17525-31.
Braz JC, Bueno OF, Liang Q, Wilkins B, Braunwart J, Glascock BJ, Klevitsky R, Kimball TF, Hewett TE, and Molkentin JD. Inhibition of p38 MAPK promotes hypertrophic cardiomyopathy and upregulation of calcineurin-NFAT signaling. J Clin Invest 2003 May;111(10):1475-86.
Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H and Robbins J. Reengineering Inducible Cardiac-specific Transgenesis with an Attenuated Myosin Heavy Chain Promoter. Circ Res. 2003 Apr 4;92(6):609-16.
Liang Q, and Molkentin JD. Divergent signaling pathways converge on GATA4 to regulate cardiac hypertrophic gene expression. J Mol Cell Cardiol. 2002 Jun;34(6):611-6.
Liang Q, Donthi RV, Kralik PM, and Epstein PN. Elevated hexokinase increases cardiac glycolysis in transgenic mice. Cardiovasc Res 2002 Feb 1; 53(2):423-30.
Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, and Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002 Jan; 51(1):174-81.
Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, and Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 2001 Nov; 21(21):7460-9.
Charron F, Tsimiklis G, Arcand M, Robitaille L, Liang Q, and Molkentin JD, Meloche S, and Nemer M. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev. 2001 Oct 15;15(20):2702-2719.
Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, and Molkentin JD. The transcriptional factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 2001 Aug 10; 276(32):30245-53.
De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, and Molkentin JD. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 2001 Mar 13; 98(6):3322-3327.
Liang Q, Carlson EC, Borgerding AJ, and Epstein PN. A transgenic model of acetaldehyde overproduction accelerates alcohol cardiomyopathy. J Pharmacol Exp Ther 1999 Nov; 291(2):766-72.
|
